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Abstract
Background Congenital myasthenic syndrome with episodic apnoea (CMS-EA) is a rare but potentially treatable cause of 
apparent life-threatening events in infancy. The underlying mechanisms for sudden and recurrent episodesof respiratory 
arrest in these patients are unclear. Whilst CMS-EA is most commonly caused by mutations in CHAT, the list of associated 
genotypes is expanding.
Methods We reviewed clinical information from 19 patients with CMS-EA, including patients with mutations in CHAT, 
SLC5A7 and RAPSN, and patients lacking a genetic diagnosis.
Results Lack of genetic diagnosis was more common in CMS-EA than in CMS without EA (56% n = 18, compared to 7% 
n = 97). Most patients manifested intermittent apnoea in the first 4 months of life (74%, n = 14). A degree of clinical improve-
ment with medication was observed in most patients (74%, n = 14), but the majority of cases also showed a tendency towards 
complete remission of apnoeic events with age (mean age of resolution 2 years 5 months). Signs of impaired neuromuscular 
transmission were detected on neurophysiology studies in 79% (n = 15) of cases, but in six cases, this was only apparent 
following specific neurophysiological testing protocols (prolonged high-frequency stimulation).
Conclusions A relatively large proportion of CMS-EA remains genetically undiagnosed, which suggests the existence of 
novel causative CMS genes which remain uncharacterised. In light of the potential for recurrent life-threatening apnoeas 
in early life and the positive response to therapy, early diagnostic consideration of CMS-EA is critical, but without specific 
neurophysiology tests, it may go overlooked.
Keywords Congenital myasthenic syndrome · Neuromuscular disease · Neurophysiology · Neuromuscular junction
Background
Congenital myasthenic syndromes (CMS) are a group 
of disorders caused by mutations in genes encoding pro-
teins responsible for the function and integrity of the 
neuromuscular junction (NMJ), resulting in impairment of 
the safety margin necessary for reliable neuromuscular trans-
mission. The first identified mutations were in genes encod-
ing subunits of the acetylcholine receptors (AChRs), and 
these remain the most common subtypes of CMS worldwide 
today [1]. However, in recent years the discovery of CMS-
related genes has accelerated, and to date over 30 genes have 
been implicated (Fig. 1).
Although the clinical spectrum is increasingly diverse, 
CMS are characterised by fatigable weakness typically of 
early onset, a positive family history, and abnormal neuro-
physiology tests, namely repetitive nerve stimulation (RNS) 
or single-fibre EMG (SFEMG) [1]. In RNS, supramaximal 
electrical stimulation is delivered to a motor nerve via sur-
face electrodes. In normal muscle, the resulting response 
(known as the compound muscle action potential or CMAP) 
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amplitude remains constant over a wide range of frequen-
cies, since the safety margin for neuromuscular transmission 
is large. In patients with abnormalities of neuromuscular 
transmission however, the CMAP amplitude can vary with 
repetitive stimulation. In pre-synaptic disorders involving 
defects of neurotransmitter release, the baseline CMAP 
amplitude is characteristically small, with high-frequency 
nerve stimulation causing an incremental CMAP response 
as a result of calcium build-up in the pre-motor terminal. 
In contrast, in post-synaptic disorders the slight reduction 
in the release of the neurotransmitter acetylcholine (ACh) 
caused by low-frequency stimulation can cause the end-plate 
potential to fall below the threshold required to generate a 
muscle action potential in a proportion of the muscle fibres. 
This results in decrement of the CMAP amplitude. However, 
in many cases, whether the disorder is pre- or post-synaptic 
cannot be effectively differentiated using neurophysiological 
testing alone.
In CMS due to mutations in the gene encoding the pre-
synaptic choline acetyltransferase (CHAT), the deficit is not 
in calcium-triggered ACh release, but in re-synthesis of ACh 
following re-uptake by the nerve terminal [2, 3]. Since the 
terminal contains a large reserve pool of ACh vesicles, a 
decremental response on RNS is only apparent once this 
pool has been exhausted. Hence, low-frequency stimulation 
typically produces no decrement, with the abnormality only 
becoming apparent following prolonged high-frequency 
nerve stimulation (e.g. 10 Hz for 5 min).
SFEMG determines the variability in the latency of 
neuromuscular transmission for individual muscle fibres 
within the same motor unit, or “jitter”. Increased jitter is 
more sensitive for detecting impaired neuromuscular trans-
mission than RNS, but is less specific since the findings are 
essentially identical for both pre- and post-synaptic disorders 
and hence must be interpreted along with clinical symptoms 
and signs.
CMS may be particularly difficult to diagnose in neo-
nates, in whom non-specific features such as generalised 
hypotonia, arthrogryposis and poor suck or cry may be 
the only clinical signs. In this age group, certain subsets 
of CMS may be associated with life-threatening episodic 
apnoea (CMS-EA); a rare, but potentially treatable cause 
of apparent life-threatening events (ALTEs). Whilst CMS-
EA was initially described in association with mutations 
in CHAT [2], the genetic basis has expanded, and several 
more recently described CMS genes have been shown to be 
associated with EA (Table 1). Genetic diagnosis for these 
conditions is all the more imperative given that effective 
treatments may prevent these life-threatening crises, but 
treatment response varies depending on the genetic subtype. 
The underlying mechanism of EA in disorders of neuro-
muscular transmission is unknown. We reviewed the clinical 
course of 19 patients with CMS-EA, to demonstrate poten-
tial diagnostic pitfalls and to assess long-term prognosis.
Methods
Clinical information was reviewed from 34 patients who 
currently attend the CMS clinic at the John Walton Mus-
cular Dystrophy Research Centre, Newcastle Upon Tyne, 
United Kingdom, and 929 patients from around the world 
who were referred to our laboratory for genetic testing 
between 1997 and 2011 in the context of a clinical suspi-
cion of CMS following review by experienced neuromus-
cular clinicians [4]. Patients had convincing evidence of 
CMS on the basis of clinical features, neurophysiological 
studies, laboratory investigations (including measurement 
of AChR antibodies and serum creatine kinase) and, in 
many cases, a prior muscle biopsy. EA was noted as being 
present where the clinician had recorded recurrent periods 
of respiratory arrest during the disease course; patients 
described as having respiratory insufficiency (causing 
inadequate oxygenation) but lacking clear description of 
recurrent apnoeic events (with cessation of respiration) 
were not included. CMS-EA was clearly described in 
32 patients; however, detailed clinical information and 
follow-up were available for 19 CMS-EA patients. For 
these cases, clinical, genetic and neurophysiological data 
were retrospectively reviewed. Genomic DNA samples or 
EDTA blood were provided to our laboratory from neuro-
muscular and neurology centres worldwide. Sanger-based 
mutation screening was carried out on a gene-after-gene 
basis according to phenotype. In one case, which has been 
previously described, the causative gene (MYO9A) was 
identified following whole exome analysis [5]. Informed 
Fig. 1  Heterogeneity of genetic defects in CMS: Mutations are 
described in genes encoding pre-synaptic, synaptic and post-syn-
aptic proteins, proteins of the extracellular matrix and dystrophin-
associated glycoprotein complex and in ubiquitously expressed pro-
teins involved in glycosylation (GFPT1, DPAGT1, ALG2, ALG14, 
GHMPPB) and mitochondrial function (SLC25A1) which may act 
at multiple sites. Genes in which mutations have been previously 
described in patients with EA are highlighted in red
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consent was obtained from all participants by local 
institutions. All genetically undiagnosed patients had 
been screened for mutations in CHAT, RAPSN, CHRNE, 
COLQ, DOK7, CHRNA1, CHRND, CHRNB1, SLC5A7 and 
SLC18A3. Neurophysiological assessment was performed 
at local institutions according to protocols described pre-
viously [6, 7]. Decrement was defined as a decrease in 
CMAP amplitude of 10% or more between the first and 
fourth CMAPs.
Results
Episodic apnoea was described in 3% (n = 32/963) of CMS 
cases. Of the CMS-EA cases, 44% (n = 14/32) were geneti-
cally diagnosed, compared with 93% (n = 866/963) of all 
CMS cases. The most common causative mutations were in 
the CHAT gene (16% of CMS-EA cases), with mutations in 
COLQ (9%), RAPSN (6%), SLC5A7 (6%), MYO9A (3%) and 
CHRNE (3%) being causative for the remainder of the cases 
with genetic diagnoses (Fig. 2).
In 13 cases, there was insufficient information on 
long-term follow-up and these were excluded from fur-
ther analysis. Clinical features, neurophysiology and man-
agement are described, therefore, for the remaining 19 
cases (Table 2).
Clinical features
All cases were proband, apart from cases 14 and 15 who 
are siblings. There was no family history of a neuromuscu-
lar disorder in any case, and consanguinity was reported in 
only two families. The disease manifested at birth in 84% 
(n = 16) of cases, with the remaining three cases present-
ing within the first 2 months of life. Signs present at birth 
were hypotonia (16 cases) and arthrogryposis (4 cases). 
Table 1  CMS genes associated with EA
Gene Protein and function Clinical features
CHAT Choline acetyltransferase (ChAT); re-synthesis of acetylcholine 
(ACh) from choline and acetyl-CoA in pre-synaptic nerve 
terminal [2]
Can exhibit striking clinical variability both between and within 
families. Positive response to AChEIs is seen in almost all 
cases [3, 22]
RAPSN Rapsyn; post-synaptic scaffolding protein, interacts with AChRs 
to induce clustering [23]
Two main phenotypes: late-onset with fatigable limb weakness, 
early onset characterised by arthrogryposis, high-arched pal-
ate, and facial, cervical and bulbar weakness [24–26]
CHRNE 
(fast 
channel)
Epsilon subunit of AChR, altered kinetic properties following 
binding of ACh to receptor [27, 28]
Severe weakness with crises [29]
SLC5A7 High-affinity choline transporter 1, resynthesises ACh in the pre-
synaptic nerve terminal [30]
Phenotypes range from severe form with arthrogryposis, hypoto-
nia and early lethality, to neonatal onset CMS with prominent 
EA [20]
SLC18A3 Vesicular acetylcholine transporter (VAChT), uptake of ACh 
into pre-synaptic vesicles [20]
Ptosis, ophthalmoplegia and fatigability. Deterioration of symp-
toms in cold temperature described in one case [20]
COLQ ColQ, collagenic tail of AChE which anchors AChE in the post-
synaptic membrane [31, 32]
Broad phenotype, from adult onset limb girdle CMS to early 
onset severe and progressive forms. Slowing of the pupillary 
light reflex (25% of cases). Worsening with AChEI therapy 
[31, 33]
CHRND Delta subunit of AChR Phenotype overlapping with rapsyn-CMS [34–36]
SCN4A Voltage gated sodium channel (Nav1.4), influx of sodium ions 
into post-synaptic membrane and generation of muscle action 
potential [37, 38]
Relatively severe limb weakness, ophthalmoplegia and ptosis. 
Apnoeic attacks which persisted from infancy into early adult-
hood are described [38]
MYO9A Unconventional myosin Myo9A, presumed pre-synaptic function 
[5]
Identified in two families, neonatal onset EA which responded 
dramatically to pyridostigmine and 3,4-DAP is described [5]
Fig. 2  Proportion of CMS-EA subtypes in our patient cohort (n=32)
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Antenatal complications were recognised in 42% (n = 8) 
of patients, and included reduced foetal movements and/or 
polyhydramnios.
Age of onset of EA was variable. Most patients had 
their first apnoea in the hours following birth (n = 5, 26%) 
or in the first 4 weeks of life (n = 5, 26%). For four cases 
(21%), the first apnoeic event occurred between the age of 
1–4 months, and four cases developed EA between 4 and 
12 months of age. In one case, EA did not occur until the 
age of 18 months.
Cognitive development was abnormal in nine cases 
(47%); in three cases, this was severe and considered to be 
secondary to hypoxic brain damage. Brain MRI was avail-
able for ten patients, and described as normal in seven, with 
two cases showing features in-keeping with hypoxic ischae-
mic encephalopathy, and one case (with CHAT-CMS) show-
ing hypoplasia of the cerebellar vermis.
Median diagnostic delay from first symptoms to the 
clinical diagnosis of CMS (prior to genetic confirmation) 
was 8 months (range 1–96 months). Differential diagno-
ses included laryngomalacia, epilepsy, cardiac conduction 
defects, congenital hypothyroidism, Prader–Willi syndrome 
and spinal muscular atrophy.
Apnoeic events and respiratory function
Infections, including respiratory tract infections, were the 
most common precipitating factor for apnoeas, reported 
in 74% (n = 14) of patients (Table 3). Apnoeas were also 
reported during feeding, stress, crying, increased activ-
ity and increased environmental temperature. Frequency 
of apnoeas varied significantly, independent of genotype, 
from approximately one episode per month, to very fre-
quent episodes occurring up to 40 times per day.
During apnoeic episodes, myasthenic features typically 
worsened, with worsening of hypotonia, bulbar weakness 
and ptosis reported in 14, 6 and 4 cases, respectively. 
Approximate duration of events ranged from 30 s to over 
30 min (persisting until the patient was intubated and 
ventilated, and resulting in permanent brain damage), but 
mean duration of a typical event was 2 min.
There was significant morbidity and mortality in the 
cohort, with two patients having died following pro-
longed apnoeas, aged 11 months (genetically undiag-
nosed) and 3 years (with RAPSN mutations), respectively, 
and a further case with severe hypoxic brain injury being 
permanently ventilated (SLC5A7 mutations). However, 
overall progressive improvement and tendency towards 
resolution of apnoeic episodes was reported in the major-
ity of cases (Fig. 3). For 11 cases there was complete 
remission of apnoeas (mean age of resolution 2 and 
5 months). A further five cases showed tendency towards 
remission but still experienced apnoeas during infections. Ta
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There was no genotype–phenotype correlation between 
cases who had remission of EA and those who still expe-
rienced apnoeas.
Neurophysiology
All patients had neurophysiological assessment; 4 cases 
had RNS and SFEMG, and 15 cases had been investigated 
using RNS alone. Abnormal RNS was seen in 15/19 cases 
(79%); in four cases, in whom only RNS was performed, no 
decrement was detected. In 5 of the 15 cases with abnormal 
RNS, stimulation at 3 Hz was borderline or negative, but 
prolonged high-frequency RNS (10 Hz for 5 min) revealed 
marked decrement. In a further patient (genetically undiag-
nosed) increment was detected on prolonged stimulation. 
All cases who had SFEMG in addition to RNS demonstrated 
increased jitter.
Management
18 cases had been treated with acetylcholinesterase inhibi-
tors (AChEIs) at some point. Of these, 67% (n = 12) had a 
sustained clinical improvement, which included all patients 
with mutations in RAPSN and CHAT, one patient with 
SLC5A7 mutations and seven patients who were genetically 
undiagnosed. Transient improvement but subsequent dete-
rioration following commencement of AChEIs was seen in 
two patients (both genetically undiagnosed). AChEIs had 
no effect in four cases (three genetically undiagnosed, and 
one SLC5A7-CMS). The β2-agonist salbutamol resulted in 
clinical improvement in three cases (genetically undiag-
nosed, fast channel syndrome and CHAT-CMS), transient 
improvement in one case (undiagnosed) and no response 
in the remaining three cases (one undiagnosed, and two 
with SLC5A7-CMS). 3,4-Diaminopyridine (3,4-DAP) was 
used as an adjunctive therapy in two cases, resulting in 
improvement in one (with CHAT-CMS) and no response 
in the other (genetically undiagnosed). All six cases in 
whom abnormal RNS had only been detected following 
prolonged high-frequency stimulation had clinical benefit 
from AChEI therapy.
Most patients (n = 14, 74%) had normal respiratory func-
tion between apnoeic events. Three cases required noctur-
nal non-invasive ventilation (one with CHAT-CMS and two 
genetically undiagnosed cases), and one was permanently 
ventilated via tracheostomy. Hospital attendances were com-
mon, with 41% (n = 8) of cases requiring frequent (> 1 per 
year) admissions. Fourteen patients had required ventilation 
during periods of respiratory crisis (11 invasive and 3 non-
invasive ventilation).
Table 3  Apnoeic events and respiratory function in our patient cohort
LRTI lower respiratory tract infection
Precipitating events Associated symptoms during apnoea Recurrent LRTI Respiratory function 
between episodes
Case 1 Feeding, infection, stress Hypotonia, bulbar weakness, ptosis Yes Normal
Case 2 Feeding, infection, stress Hypotonia Previously, now resolved Normal
Case 3 Infection Hypotonia Previously, now resolved Normal
Case 4 Infection, feeding Hypotonia Yes Normal
Case 5 Infection, during sleep Hypotonia, bulbar weakness Yes Normal
Case 6 Stress, infection, higher temperature Ptosis, bulbar weakness, hypotonia Previously, now resolved Normal
Case 7 Crying Hypotonia No Normal
Case 8 Infection None noted Previously, now resolved Normal
Case 9 Feeding, infection Ptosis, bulbar weakness, hypotonia No Normal
Case 10 Infection Hypotonia Yes Permanently ventilated
Case 11 Infection, feeding, crying None noted Yes Normal
Case 12 Feeding, infection Hypotonia, facial weakness Yes Impaired
Case 13 Feeding No Yes Normal
Case 14 Feeding Hypotonia, ptosis, cyanosis Yes Not assessed
Case 15 Infection, increased activity, sleep Hypotonia Yes Normal
Case 16 Infection, increased activity, sleep Hypotonia, bulbar weakness Yes Normal
Case 17 Feeding Hypotonia No Normal
Case 18 Feeding, infection, during sleep Hypotonia, cyanosis Yes Impaired
Case 19 Infection, feeding Hypotonia, cyanosis Yes Impaired
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Discussion
Apparent life-threatening events (ALTEs), defined as epi-
sodes characterised by some combination of apnoea, skin 
colour change, change in muscle tone and choking or gag-
ging [8], have an extremely broad differential diagnosis. 
Causes include epilepsy, cardiac arrhythmia or structural 
cardiac defects, gastro-oesophageal reflux disease, respira-
tory tract infections and upper airway obstruction [9–12]. 
ALTEs are most common in the first 10 weeks of life, with 
cyanosis and apnoea often being the most prominent or 
only symptoms [11]. CMS is rarely considered as a pos-
sible differential diagnosis for ALTEs, thus many patients 
undergo extensive investigation before the possibility is con-
sidered. In our cohort, average diagnostic delay was sub-
stantial at 8 months. Worsening of myasthenic symptoms 
during apnoeas was frequently observed, and these features 
may provide a diagnostic clue. In practice, however, many 
patients may be admitted directly to intensive care units and 
may not be examined by a paediatric neurologist or neuro-
muscular specialist during these crises.
In early infancy, abnormal neurophysiology tests may 
be the only indication of a NMJ disorder. However, we 
observed in this cohort that without specific neurophysi-
ological assessment, a pre-synaptic abnormality may go 
overlooked. In 32% (n = 6) of cases, no abnormality was 
observed at low-frequency RNS, with decrement or incre-
ment only becoming apparent following prolonged high-
frequency stimulation. In two of these cases, the genetic 
diagnosis was of ChAT deficiency, in which re-synthesis of 
ACh is known to be impaired. In the other four cases, the 
genetic diagnosis was unknown, but it may be that these also 
affect proteins involved in this pathway. Failure to perform 
this additional test could result in the diagnosis of CMS-EA 
being discounted. Furthermore, all of these cases showed a 
positive response to AChEI therapy. Such prolonged studies 
can be uncomfortable for the patient, and may require seda-
tion. Nevertheless, given the risk of fatal apnoeas if the diag-
nosis is missed, and the potential for clinical improvement 
with AChEIs, these prolonged studies should be performed 
if deficiency of ACh re-synthesis is suspected.
The underlying mechanism(s) giving rise to these sudden 
and recurrent apnoeas is yet to be characterised. Respira-
tory control mechanisms respond to input from neural and 
chemical receptors, which are integrated by the respiratory 
centres in the medulla and pons. These subsequently provide 
neuronal drive to respiratory muscles, maintaining upper air-
way patency and determining the level of ventilation. Recur-
rent apnoea could be due to an abnormality at any point 
along this axis. The majority of mutations causing CMS-
EA lead to pre-synaptic defects (Fig. 1), which have impor-
tant functions for both central and neuromuscular synaptic 
function. This, along with the tendency for patients to have 
normal respiratory function between apnoeas, could point 
to a centrally mediated mechanism. In addition, the pro-
portion of patients with impaired cognitive function in our 
cohort (47%) was higher than expected and is not something 
that has been previously well-characterised in disorders of 
the NMJ. Any impairment of higher function in CMS-EA 
patients is often explained by hypoxic brain damage due 
to repeated respiratory failure, although the possibility of 
impaired CNS maturation due to reduced neurotransmitter 
in central cholinergic neurons has not been fully explored. 
The most common CMS-EA gene, CHAT, has important 
functions in both central and peripheral synapses, and defi-
ciency of ChAT has been reported in Alzheimer’s disease, 
idiopathic Parkinson’s disease, Huntington’s disease and 
schizophrenia [13–16]. Furthermore, in cases of sudden 
infant death syndrome, decreased activity of ChAT has been 
demonstrated in the CNS [17, 18]. Cognitive and behav-
ioural have also been described in the recently identified 
CMS subtype due to mutations in SLC5A7, which encodes 
the high-affinity choline transporter 1, necessary for uptake 
of choline from the synaptic space for the synthesis of ACh 
at central and peripheral cholinergic synapses [19]. A further 
CMS-EA gene involved in ACh release, SLC18A3, encodes 
the vesicular acetylcholine transporter (VAChT), which 
mediates the vesicular storage of ACh in the central and 
peripheral nervous system. SLC18A3 mutations are associ-
ated with a severe CMS phenotype and learning difficulties 
are also described [20, 21]. The CMS-EA genes SNAP25B, 
VAMP1 and MUNC13 encode proteins of the SNARE com-
plex. These are essential for calcium-triggered exocytosis at 
central and neuromuscular synapses; therefore, it is unsur-
prising that CMS due to mutations in these genes may be 
associated with epilepsy and impaired brain development 
[22, 23]. Abnormalities of the CNS have also been reported 
in CMS due to mutations in the unconventional myosin gene 
Fig. 3  Resolution of apnoeic events over time: For the majority of 
cases, the period of recurrent EAs (orange) during a patient’s life 
span (gray) began in the first months of life and resolved in early 
childhood. Cases marked * are deceased
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MYO9A. MYO9A also appears to have pre-synaptic function 
and localization at the NMJ, although the mechanism for 
NMJ dysfunction in these patients is yet to be determined 
[5].
Administration of one or more drugs is indicated once 
the diagnosis of CMS-EA is established. Several drugs 
have shown convincingly positive effects in reducing the 
frequency of apnoeas, including AChEIs, 3,4-DAP and sym-
pathomimetics (ephedrine or salbutamol). Because of the 
sudden nature of these attacks, parents should be provided 
with an inflatable rescue bag and fitted mask, trained in CPR 
and may be provided with a home apnoea monitor. Parents 
may also be instructed to give additional AChEI doses dur-
ing infection or other potential precipitating events.
We recognise that this study has several limitations. We 
include a small number of patients, contributed to by the 
rarity of the condition. Data were collected retrospectively 
and over a long period of time (1997–2011) during which 
the awareness of CMS and availability for genetic testing 
has increased. However, even in this patient cohort, who 
continues to be tested for new causative CMS genes as they 
are discovered, a relatively large proportion (56%) of cases 
remain genetically undiagnosed. CMS-EA is a challenging 
diagnosis, with several mimics, and this proportion could 
suggest an alternative diagnosis other than a neuromuscular 
transmission defect in these patients. However, it may also 
reflect further CMS causing genes which have not yet been 
discovered.
Given the likelihood of recurring episodes, the poten-
tial for psychomotor impairment due to secondary hypoxic 
brain damage, and the positive effect of available treatments, 
CMS-EA is an important diagnosis not to miss. Prompt diag-
nosis and initiation of treatment and ventilatory support is 
imperative in early life, when EA may be frequent, but the 
majority of cases will exhibit a tendency towards remission. 
Improved understanding of the mechanism of this condition 
may provide insights into further causative genes for geneti-
cally undiagnosed patients, and lead to improved diagnostic 
and treatment strategies.
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